Abstract: Described is a process for producing field butane. The process includes increasing the n-butane concentration in field butane. The process may include a concentration process that includes distillation and a thermal cracking process.

Abstract: Systems and processes for producing isomerized alkenes are disclosed. The systems mainly include an isomerization unit, a dehydrogenation unit, and a MTBE synthesis unit. A hydrocarbon stream is fed into the isomerization unit to form iso-alkanes in a sulfur free hydrocarbon stream. The sulfur free hydrocarbon stream is heated and then combined with a sulfur-containing hydrocarbon stream comprising sulfur containing compounds to form a reactant feed stream to the dehydrogenation unit. The iso-alkanes is dehydrogenated to form iso-alkenes. The formed iso-alkenes comprising isobutylene can be used as a feed stock for the MTBE synthesis unit.

Abstract: The present invention provides methods for the preparation of halogenated alkenes from halogenated alkanes using a homogeneous catalyst.

Abstract: The invention relates to a process comprising contacting a composition comprising a (hydro)halocarbon and a compound of formula Rf—C?CX with a basic solution comprising an hydroxide, an alkoxide and/or an amide to reduce the concentration of Rf—C?CX, wherein Rf is a perfluorinated alkyl group and X is H, F, Cl, Br, or I. The invention further relates to process for preparing a (hydro)halocarbon comprising (i) converting a starting material, optionally in the presence of HF and/or a catalyst, to a composition comprising the (hydro)halocarbon and a compound of formula Rf—C?CX, wherein Rf is a perfluorinated alkyl group and X is H, F, Cl, Br, or I; (ii) contacting the composition with a basic solution comprising an hydroxide, an alkoxide and/or an amide to reduce the concentration of the compound of formula Rf—C?CX; and (iii) recovering the (hydro)halocarbon.

Abstract: A process of producing allyl alcohol by reacting glycerin with ReO3—Al2O3 in the presence of gamma-valerolactone (GVL) in a reactor is described. More specifically, a process to produce allyl alcohol, comprising the step of: a) reacting glycerin with ReO3—Al2O3 in the presence of an inert solvent, GVL, in a reactor, and b) collecting the product comprising allyl alcohol.

Abstract: The invention relates to fused cyclooctyne compounds, and to a method for their preparation. The invention also relates to a conjugate wherein a fused cyclooctyne compound according to the invention is conjugated to a label, and to the use of these conjugates in bioorthogonal labeling, imaging and/or modification, such as for example surface modification, of a target molecule. The invention further relates to a method for the modification of a target molecule, wherein a conjugate according to the invention is reacted with a compound comprising a 1,3-dipole or a 1,3-(hetero)diene.

Abstract: The present invention relates to a process for preparing 4-chlorobenzyl propargylether comprising a step (a) of reacting 4-chlorobenzyl chloride with propargyl alcohol in the presence of a base and a phase transfer catalyst, wherein the reaction mixture comprises at least two phases, wherein one phase is an organic phase and one phase is an aqueous phase.

Abstract: The present invention relates to a method of preparing cyclododecanone. According to the present invention, a method of preparing cyclododecanone which allows implementation of a high conversion rate and minimization of production of unreacted materials and reaction by-products may be provided. In addition, the present invention implements a high conversion rate and a high selectivity even by a simplified process configuration, and thus may be usefully utilized in an economical method of preparing laurolactam, allowing commercially easy mass production.

Abstract: A method for manufacturing 1,4-bis(4-phenoxybenzoyl)benzene, including: reacting terephthaloyl chloride with diphenyl ether in a reaction solvent and in the presence of a Lewis acid, so as to obtain a product mixture including a 1,4-bis(4-phenoxybenzoyl)benzene-Lewis acid complex; contacting the product mixture with an aqueous solution, so as to obtain an aqueous phase containing the Lewis acid and an organic phase containing 1,4-bis(4-phenoxybenzoyl)benzene; heating at least the second phase up to a maximum temperature, followed by cooling the second phase down to a separation temperature; subjecting at least the second phase to a solid/liquid separation step at the separation temperature, so as to recover solid 1,4-bis(4-phenoxybenzoyl)benzene.

Abstract: A process of recovering propylene and N-butyraldehyde from a purge gas includes forming a first product stream including N-butyraldehyde by reacting propylene and a first synthesis gas in the presence of a first catalyst in a first reactor and a second reactor; withdrawing a mixed stream from the second reactor; separating a liquid stream and purge gas from the mixed stream and recycling the liquid stream to the second reactor; reacting the purge gas and a second synthesis gas in the presence of a second catalyst in a purge gas reactor to form a second product stream including N-butyraldehyde; withdrawing the second product stream including N-butyraldehyde from the purge gas reactor and combining the second product stream including N-butyraldehyde and the first product stream including N-butyraldehyde; and withdrawing a stream including N-butyraldehyde from the purge gas reactor and recovering N-butyraldehyde from the stream including N-butyraldehyde product stream.

Abstract: The present invention provides novel compounds as well as compositions and methods using the same for preventing and/or treating degenerative disorders of the central nervous system and/or lysosomal storage disorders. In particular, the present invention provides methods for preventing and/or treating Parkinson's disease, Alzheimer's disease and/or Gaucher's disease.

Abstract: A method of producing an N,N-disubstituted amide of the present invention is a method of reacting a nitrile with an alcohol in the presence of a catalyst, wherein the nitrile is a compound represented by R1CN (R1 represents an alkyl group having 10 or less carbon atoms or an aryl group having 10 or less carbon atoms), wherein the alcohol is a compound represented by R2OH (R2 represents an alkyl group having 10 or less carbon atoms), wherein the catalyst is a metal salt represented by MXn (M represents a metal cation having an oxidation number of n, X represents a monovalent anion including a substituted sulfonyl group represented by —S(?O)2—R3 (R3 represents a hydrocarbon group having 10 or less carbon atoms or a group in which some or all of hydrogen atoms in the hydrocarbon group are substituted with fluorine atoms), and n represents an integer of 1 to 4), a substituent bonded to a carbon atom in a carbonyl group of the N,N-disubstituted amide is R1, and two substituents bonded to nitrogen atoms in an amide

Abstract: The method for producing pentamethylene diisocyanate includes a reaction step, in which carbonyl chloride is allowed to react with pentamethylenediamine to produce a reaction mixture containing pentamethylene diisocyanate and a tar component containing a chlorine-containing component; a heating step, in which the reaction mixture is heated; and a purification step, in which the reaction mixture after the heating step is purified to separate the pentamethylene diisocyanate from the tar component, wherein in the heating step, the reaction mixture is heated without removing the tar component from the reaction mixture.

Abstract: Biobased diisocyanates are derived from 3-petadecyl phenol, which is derived from Cardanol harvested from cashew nutshell liquid food waste. The biobased diisocyanates are of the formulas: wherein R is an alkyl chain C15H31 (n-pentadecyl); R1=CH3 or COCH3; and R2 is an alkylene of from about 1 to 18 carbon atoms.

Abstract: Selective potassium channel agonists and methods of use thereof are disclosed. A compound, or a pharmaceutically acceptable salt thereof, having a formula I wherein R1 is H or optionally-substituted alkyl; R2 is optionally-substituted C1-C6 alkyl or optionally-substituted cyclopropyl; R3 and R4 are each independently H or optionally-substituted alkyl; R5 is H, optionally-substituted alkyl, acyl, or alkoxycarbonyl; R6 and R7 are each independently H, optionally-substituted alkyl, or R6 and R7 together form a carbocycle; R8 is substituted phenyl or optionally-substituted pyridinyl, provided that if R8 is substituted phenyl, then R2 is optionally-substituted cyclopropyl; and R9, R10 and R11 are each independently H, halo, or optionally-substituted alkyl.

Abstract: Provided herein are compounds, such as compounds of Formula I, that bind to androgen receptors and/or modulate activity of androgen receptors. Also provided are methods for making and using such compounds. Also provided are compositions including such compounds and methods for making and using such compositions.

Abstract: Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).

Abstract: Compounds that are inhibitors of retinoic acid inducible P450 (CYP26) enzymes. The compounds have retinoid activity, are resistant to CYP26-mediated catabolism, act as inhibitors of CYP26B1, and are used for treating diseases that are responsive to retinoids.

Abstract: Crystalline forms of 4-acetoxy-N,N-dimethyltryptamine (psilacetin), compositions containing that crystalline form, and their methods of use are disclosed. The crystalline forms of 4-acetoxy-N,N-dimethyltryptamine (psilacetin) according to the disclosure include crystalline 4-acetoxy-N,N-dimethyltryptammonium hydrofumarate, the fumarate salt of psilacetin, and/or crystalline bis(4-acetoxy-N,N-dimethyltryptammonium) fumarate, and pharmaceutical compositions containing a crystalline form of psilacetin.

Abstract: Pharmaceutical compositions of the invention include substituted Lanicemine prodrugs useful for the treatment of conditions associated with dysregulation of NMDA receptor activity such as depression and depressive disorders through the release of Lanicemine, Prodrugs of Lanicemine have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release Lanicemine in the plasma via either an enzymatic or general biophysical release process.

Abstract: Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.

Abstract: It is provided an achiral, non-nucleosidic backbone for phosphoramidites that can be inserted with high yields in nucleic acid strands and sequence-controlled oligo(phosphodiester)s through solid phase synthesis (SPS) using a DNA synthesizer. From this backbone, platforms with useful chemical handles were synthesized, further functionalized, transformed into phosphoramidites and attached to nucleic acid strands and sequence-controlled oligo(phosphodiester)s. The backbone is based on a tertiary amine with a 3-6 carbon spacer between the central nitrogen and the two external hydroxyls. The spacer has been optimized to increase coupling yields and stability.

Abstract: The present invention relates to a crystalline form of Compound I, a salt, a solvate, or a solvate salt thereof or an amorphous form of Compound I, a salt, a solvate, or a solvate salt thereof. The present invention also provides compositions comprising the crystalline form and/or the amorphous form, therapeutic uses of the crystalline forms and/or the amorphous forms, and the compositions thereof.

Abstract: The invention relates to novel compounds that are derivatives of 1,4-benzodiazepin-2-one, having the general formula I: and being limited to structural variants 1-6: on condition that: a) structures 1 (R1=Br, R4=F), 3 (R1=OCF3, R4=H), 5 (R1=NO2, R4=Cl) and 6 (R1=NO2, R4=F) have the following substituents R2 and R3: R2=H, CH2COCH3, CH2COOCH3, CH2CONHNH2; R3=OAlk, NHAr, where Alk=C2H5, C3H7, C4H9, (CH2)2OH, (CH2)2OCH3, R5=o-, m-, p-COCH3, Cl, F, Br, NO2, CF3; b) structure 2 (R1=Cl, R4=H) has the following substituents R2 and R3: if R2=H, then R3=OAlk, NHAr, where Alk=(CH2)2OCH3, R5=m-, p-COCH3, o-, m-, p-F, Br, CF3; ?if R2=CH2COCH3, CH2COOCH3, CH2CONHNH2, then R3=OAlk, NHAr, where Alk=C2H5, C3H7, C4H9, (CH2)2OH, (CH2)2OCH3, R5=o-, m-, p-COCH3, Cl, F, Br, NO2, CF3; c) structure 4 (R1=NO2, R4=H) has the following substituents R2 and R3: if R2=H, then R3=OAlk, NHAr, where Alk=(CH2)2OCH3, R5=o-, m-, p-COCH3, Cl, F, Br,

Abstract: Provided herein are the K-Ras inhibitors of the formulae: Also provided are compositions comprising thereof for treating cancer.

Abstract: The invention relates to compounds of a new type which have a stabilizing effect and in particular provide stabilization with respect to oxidative thermal and/or actinic decomposition of or damage to organic materials. The compounds are represented by general formula I specified below. The invention further relates to a method for producing such compounds, to compositions containing said compound, to a method for stabilizing organic compounds by means of the stabilizing compounds, and to the use of the stabilizing compounds to stabilize organic materials.

Abstract: The disclosure is directed to compounds of the formula (I): and uses of such compounds to treat neurodegenerative diseases and cancers.

Abstract: Provided is a method for preparing furfural. The method comprises: mixing a plant raw material and an acid containing a —SO3H functional group for pre-treating, then mixing same with an organic acid, cooking same, and then subjecting same to solid-liquid separation, so as to obtain a hemicellulose sugar solution; introducing the resulting hemicellulose sugar solution from the upper part of a reaction kettle, and at the same time, introducing an acetic acid steam from the lower part of the reaction kettle, such that the sugar solution and the acetic acid steam come into contact in a counter-current manner and react so as to form a furfural steam; after the reaction is completed, discharging the furfural steam from the upper part of the reaction kettle; and cooling same so as to obtain a solution containing furfural.

Abstract: The present invention provides compounds as represented by structural formula (I). In formula (I), R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, and R14 are separately H or deuterium (D) independently. Moreover, at least one of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, and R14 must be D. Also provided is use of any of the compounds or its pharmaceutical composition in the preparation of a drug for treating an anxiety.

Abstract: The present invention discloses a method for preparing a cyclopenta[c]chromene compound. A cationic rare earth compound [Ln(CH)3CN)9]3+[(AlCl4)3]3?.CH3CN is used as a catalyst, and p-methyl thiophenol is used as an accelerator for a catalytic reaction of a chalcone compound so as to prepare a product; and Ln, contained in the catalyst, represents a positive trivalent rare earth metal ion and is selected from one of La, Nd, Sm, Gd and Yb. According to the method, the starting materials are easy to obtain, the reaction process is simple, the catalyst usage is low, the catalyst is universally applicable to various substituted 2-hydroxy chalcones, and the obtained cyclopenta[c]chromene compound has not been reported. The catalyst synthesis method is simple and easy to obtain, and the yield of the target product is high.

Abstract: Disclosed is a compound represented by chemical formula (1). In addition, disclosed is an organic electronic element comprising: a first electrode; a second electrode; and an organic layer between the first electrode and the second electrode, wherein the organic layer contains the compound represented by chemical formula (1). Light-emitting efficiency, stability and lifespan may be enhanced when the compound represented by chemical formula (1) is contained in the organic layer.

Abstract: Provided herein are inhibitors of transmembrane protein 16A (TMEM 16A), a Ca2+-activated CI? channel expressed widely in mammalian epithelia, as well as in vascular smooth muscle and some tumors and electrically excitable cells. TMEM16A inhibitors have potential utility for treatment or management of disorders of epithelial fluid and mucus secretion, hypertension, some cancers, pain, and other diseases.

Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of CRBN, and the treatment of CRBN-mediated disorders.

Abstract: The present disclosure describes carbamate and urea compounds as novel multikinase inhibitors and methods for preparing them. The pharmaceutical compositions comprising such multikinase inhibitors and methods of using them for treating cancer, infectious diseases, and other disorders associated with kinases are also described.

Abstract: Disclosed are a class of SMAC mimetics used as IAP inhibitors, and in particular disclosed are compounds as shown in formula (I), isomers thereof, and pharmaceutically acceptable salts thereof. The IAP inhibitors are drugs for treating cancers, in particular breast cancer.

Abstract: In order to provide a novel ?-conjugated compound capable of increasing the light-emission efficiency of an organic electroluminescence element, for example, this ?-conjugated compound has a structure indicated by general formula (1). (In general formula (1): Z1-Z6 each independently indicate a hydrogen atom, a deuterium atom, an electron-donating group D, or an electron-withdrawing group A; at least out of two among Z1-Z6 is an electron-donating group D and the other is an electron-withdrawing group A; and at least one ortho position combination Z1 and Z2, Z2 and Z3, Z3 and Z4, Z4 and Z5, Z5 and Z6, or Z6 and Z1 among Z1-Z6 is one combination out of an electron-donating group D and an electron-donating group D, an electron-withdrawing group A and an electron-withdrawing group A, or an electron-donating group D and an electron-withdrawing group A.

Abstract: Provided herein are 4-aminoisoindoline-1,3-dione compounds having the following structure: wherein R, Ring A, and n are as defined herein, compositions comprising an effective amount of a 4-aminoisoindoline-1,3-dione compound, and methods for treating or preventing disorders.

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable slat thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: Provided herein are compounds and compositions useful in increasing PPAR? activity. The compounds and compositions provided herein are useful for the treatment of PPAR? related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).

Abstract: Disclosed are 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones represented by the Formula (I): wherein Ar, R1-R6 are defined herein. Compounds having Formula (I) are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity.

Abstract: There are provided compounds having formula (I), in which: X1 and X2 are selected from certain combinations of O, S, SO and SO2; X3 is selected from CH, CF and N; X4 is selected from CH and N; X6, X6? and X6? are selected from H, halogen, and certain alkyl, haloalkyl, alkoxy, hydroxyalkyl, and amide groups; X7 and X7? are selected from H, halogen, and certain alkyl, haloalkyl, alkoxy, hydroxyalkyl, aminoalkyl and amide groups, or both X7 and X7? together form a cycloalkyl or heterocycle; and A is selected from certain optionally substituted, alkoxy, piperazinyl and pyrrolidinyl groups. Also provided are compositions comprising these compounds, as well as uses/methods related thereto, including treatment of diseases and conditions associated with GPR119 dysregulation, Type 2 diabetes mellitus, and related metabolic disorders.

Abstract: Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as pesticides, especially as fungicides.

Abstract: Provided herein are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

Abstract: Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I) or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein B, Z, Ra, Rb, Rc, R1, L, L1 and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

Abstract: This application features pyrazol-3-one compounds that activate pro-apoptotic BAX. Also featured are methods of using such compounds, e.g., for the treatment or prevention of diseases, disorders, and conditions associated with deregulated apoptosis of cells (e.g., insufficient apoptosis of diseased or damaged cells or essentially the absence of apoptosis of diseased or damaged cells).

Abstract: Novel compounds useful for treating and/or preventing HCMV infections are provided.

Abstract: The invention relates to small molecule imaging tools, specifically compounds of formula II and to pharmaceutically acceptable acid addition salts thereof, wherein R1-R6 have any of the values defined in the specification.

Abstract: Low-temperature syntheses of thymoquinone/harmaline compounds are provided which give increased yields of desirable products having molecular weights of from about 360-380. The syntheses involve carrying out reactions between thymoquinone and harmaline and a non-interfering solvent at a temperature of less than about 10° C.

Abstract: The present disclosure is directed to methods of treating or ameliorating various conditions by the administration of a BCN057, BCN512 or analogs of these compounds. The compounds can be used to reduce tumor burden in cancers, including pancreatic cancer and gastrointestinal (GI) cancer. The compounds can also be used to protect against chemotherapy induced toxicity to the GI tract. Further, they can be used to treat fibrosis and various inflammatory conditions. Analogs of BCN057 and BCN512 are also described.

Abstract: Provided herein are compounds that modulate EGFR and methods of using the same, for example to treat cancer.